Emerging drugs for alpha-1-antitrypsin deficiency

Expert Opinion on Emerging Drugs

Volumn 15, Issue 4, 2010, Pages 685-694

  Stockley, Robert A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

alpha 1 antitrypsin deficiency; COPD; neutrophil elastase; treatment

Indexed keywords

ALPHA 1 ANTITRYPSIN; ARALAST NP; AZD 9668; ELASTASE INHIBITOR; LEUKOCYTE ELASTASE; PALOVARATENE; PROLASTIN C; R 0667; RECOMBINANT PROTEIN; RESPIRA; RESPIVA; RETINOIC ACID RECEPTOR GAMMA; RETINOIC ACID RECEPTOR GAMMA AGONIST; UNCLASSIFIED DRUG; ZEMAIRA;

ALPHA 1 ANTITRYPSIN DEFICIENCY; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME REPLACEMENT; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG DESIGN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; LIVER DISEASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 78649460678     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2010.512287     Document Type: Review

References (68)

1. Willemse BW, ten Hacken NH, Rutgers B, et al. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005;26(5):835-45
2. Larson RK, Barman ML, Kueppers F, et al. Genetic and environmental determinants of chronic obstructive pulmonary disease. Ann Intern Med 1970;72(5):627-32
3. Kueppers F, Miller RD, Gordon H, et al. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med 1977;63(3):336-42
4. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009;361(27):2599-608
5. Laurell C, Eriksson S. The electrophoretic alpha 1-globulin pattern of serum in alpha 1-antitrypsin deficiency. Scand J Clin Lab Invest 1963;15:132-40
6. Eriksson S. Studies in alpha 1-antitrypsin deficiency. Acta Med Scand Suppl 1965;432:1-85
7. Gross P, Pfitzer EA, Tolker E, et al. Experimental emphysema: its production with papain in normal and silicotic rats. Arch Environ Health 1965;11:50-8
8. Stockley RA. Alpha-1-antitrypsin deficiency. In: Voelkel NF, MacNee W, editors, Chronic obstructive lung diseases 2. BC Decker Inc, Hamilton, Ontario, Canada; 2008. p. 53-62
9. Dawkins PA, Dawkins CL, Wood AM, et al. Rate of progression of lung function impairment in alpha-1-antitrypsin deficiency. Eur Respir J 2009;33:1338-44
10. Luisetti M, Seersholm N. Alpha1-antitrypsin deficiency 1: epidemiology of alpha1-antitrypsin deficiency. Thorax 2004;59(2):164-9
11. *Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J 2006;27(1):77-84
12. Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998;157(6 Pt 1):1770-8
13. Janciauskiene SM, Nita IM, Stevens T. Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem 2007;282(12):8573-82
14. Churg A, Wang X, Wang RD, et al. Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages. Am J Respir Cell Mol Biol 2007;7(2):144-51
15. Lomas DA, Evans DL, Finch JT, et al. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992;357(6379):605-7
16. Parmar JS, Mahadeva R, Reed BJ, et al. Polymers of alpha (1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 2002;6(6):723-30
17. Persson C, Subramaniyam D, Stevens T, et al. Do native and polymeric alpha1-antitrypsin activate human neutrophils in vitro? Chest 2006;129(6):1683-92
18. Belorgey D, Hagglof P, Karlsson-Li S, et al. Protein misfolding and the serpinopathies. Prion 2007;1(1):15-20
19. Morrison HM, Kramps JA, Burnett D, et al. Lung lavage fluid from patients with alpha1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clin Sci 1987;72:373-81
20. Hubbard RC, Fells G, Gadek J, et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991;88(3):891-7
21. Kuwahara I, Lillehoj EP, Lu W, et al. Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-kappaB activation via EGFR transactivation in a lung epithelial cell line. Am J Physiol Lung Cell Mol Physiol 2006;291: L407-16
22. Ho SC, Lee KY, Chan YF, et al. Neutrophil elastase represses IL-8/CXCL8 synthesis in human airway smooth muscle cells through induction of NF-kappa B repressing factor. J Immunol 2009;183(1):411-20
23. Liou TG, Campbell EJ. Nonisotropic enzyme - inhibitor interactions: a novel nonoxidative mechanism for quantum proteolysis by human neutrophils. Biochemistry 1995;34(49):16171-7
24. Liou TG, Campbell EJ. Quantum proteolysis resulting from release of single granules by human neutrophils: a novel, nonoxidative mechanism of extracellular proteolytic activity. J Immunol 1996;157(6):2624-31
25. Cepinskas G, Sandig M, Kvietys PR. PAF-induced elastase-dependent neutrophil transendothelial migration is associated with the mobilization of elastase to the neutrophil surface and localization to the migrating front. J Cell Sci 1999;112(Pt 12):1937-45
26. Morrison HM, Welgus HG, Stockley RA, et al. Inhibition of human leukocyte elastase bound to elastin: relative ineffectiveness and two mechanisms of inhibitory activity. Am J Respir Cell Mol Biol 1990;2:263-9
27. Fregonese L, Stolk J, Frants RR, et al. Alpha-1 antitrypsin Null mutations and severity of emphysema. Respir Med 2008;102(6):876-84
28. Morse JO, Lebowitz MD, Knudson RJ, et al. Relation of protease inhibitor phenotypes to obstructive lung diseases in a community. N Engl J Med 1977;296(21):1190-4
29. Gelb AF, Klein E, Lieberman J. Pulmonary function in nonsmoking subjects with alpha1 antitrypsin deficiency (MZ phenotype). Am J Med 1977;62(1):93-8
30. *SZ phenotype of alpha 1-antitrypsin deficiency: alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1996;154(6 Pt 1):1718-25
31. *S allele and COPD: a meta-analysis. Eur Respir J 2005;26(1):67-76
32. Dahl M, Tybjaerg-Hansen A, Lange P, et al. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med 2002;136(4):270-9
33. Holme J, Stockley RA. CT Scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency. Chest 2009;136(5):1284-90
34. Hill AT, Campbell EJ, Bayley DL, et al. Evidence for excessive bronchial inflammation during an acute exacerbation of COPD in patients with alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med 1999;160:1968-75
35. Sullivan A, Stockley RA. Proteinases and COPD. In: Hansel T, Barnes PJ, editors, Chronic obstructive pulmonary disease. Blackwell Publishing Ltd, Birkhauser, Boston, USA; 2007. p. 349-66
36. Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007;13(12):1423-30
37. Gadek JE, Klein HG, Holland PV, et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981;68(5):1158-65
38. Schluchter MD, Stoller JK, Barker AF, et al. Feasibility of a clinical trial of augmentation therapy for alpha (1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 2000;161(3 Pt 1):796-801
39. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998;158(1):49-59
40. Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997;10(10):2260-3
41. Wencker M, Fuhrmann B, Banik N, et al. Longitudinal follow-up of patients with alpha (1)-protease inhibitor deficiency before and during therapy with IV alpha (1)-protease inhibitor. Chest 2001;119(3):737-44
42. Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha-1 antitrypsin deficiency: a meta-analysis. J COPD 2009;6(3):177-84
43. Gevenois PA, De Vuyst P, de Maertelaer V, et al. Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1996;154(1):187-92
44. Dowson LJ, Guest PJ, Hill SL, et al. High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J 2001;17:1097-104
45. Dawkins PA, Dowson LJ, Guest PJ, et al. Predictors of mortality in alpha1-antitrypsin deficiency. Thorax 2003;58:1020-6
46. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha (1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160(5 Pt 1):1468-72
47. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009;33(6):1345-53
48. Parr DG, Dirksen A, Piitulainen E, et al. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency. Respir Res 2009;75:1-10
49. Stockley RA, Deng C, Piitulainen E, et al. Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis. Am J Respir Crit Care Med 2008;177(Suppl): abstract A419
50. Luisetti M, Sturani C, Sella D, et al. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 1996;9(7):1482-6
51. Stone PJ, Lucey EC, Snider GL. Induction and exacerbation of emphysema in hamsters with human neutrophil elastase inactivated reversibly by a peptide boronic acid. Am Rev Respir Dis 1990;141(1):47-52
52. Guarnieri F, Spencer JL, Lucey EC, et al. A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema. Proc Natl Acad Sci USA 2010;107(23):10661-6
53. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997;3(6):675-7 (Pubitemid 27264979)
54. Belloni PN, Garvin L, Mao CP, et al. Effects of all-trans-retinoic acid in promoting alveolar repair. Chest 2000;117(5 Suppl 1):235S-241S
55. Stockley RA, Stolk J. REPAIR (Retinoid treatment of Emphysema in Patients on the Alpha-antitrypsin International Registry Study results). Eur Respir J, Conference proceedings; 2009. p. 270s-271s
56. Spencer LT, Humphries JE, Brantly ML. Antibody response to aerosolized transgenic human alpha1-antitrypsin. N Engl J Med 2005;352(19):2030-1
57. Pemberton PA, Kobayashi D, Wilk BJ, et al. Inhaled recombinant alpha 1-antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. COPD 2006;3(2):101-8
58. Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alpha l-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006;17(12):1177-86
59. McNab GL, Ahmad A, Mistry D, et al. Modification of gene expression and increase in alpha1-antitrypsin (alpha1-AT) secretion after homologous recombination in alpha1-AT-deficient monocytes. Hum Gene Ther 2007;18:1171-7
60. Flotte TR, Brantly ML, Spencer LT, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004;15(1):93-128
61. Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006;17(12):1177-86
62. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci USA 2000;97(4):1796-801
63. Parfrey H, Dafforn TR, Belargey D, et al. Inhibiting polymerization: new therapeutic strategies for Z alpha1-antitrypsin-related emphysema. Am J Respir Cell Mol Biol 2004;31(2):133-9
64. Mallya M, Phillips RL, Saldanha SA, et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem 2007;50(22):5357-63
65. Stockley RA, Bayley DL, Unsal I, et al. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2002;165:1494-8
66. Needham M, Stockley RA. Exacerbations in alpha-1-antitrypsin deficiency. Eur Respir J 2005;25:992-1000
67. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000;118(5):1480-5
68. Stockley RA, Luisetti M, Miravitlles M, et al. Ongoing research in Europe: alpha one International Registry (AIR) objectives and development. Eur Respir J 2007;29:582-6